EU MIR Form Version 7.3.1 Implementation Likely Delayed To 2026: What Manufacturers Must Know

The European Commission has quietly updated its Post-Market Surveillance and Vigilance (PMSV) webpage, signaling major upcoming changes to the Manufacturer Incident Report (MIR) form used under the EU Medical Device Regulation (MDR 2017/745).

Although MIR Form Version 7.3.1 was originally expected to become operational in 2025, recent developments now suggest implementation may be delayed until 2026, with mandatory adoption likely beginning approximately four months after publication of the finalized version.

This delay is highly significant for medical device manufacturers, Authorized Representatives (ARs), importers, and regulatory affairs teams because the MIR form remains one of the most critical tools for serious incident reporting and Field Safety Corrective Action (FSCA) submissions within the EU MDR vigilance framework.

At Maven Regulatory Solutions, we support global medical device manufacturers with MDR vigilance compliance, PMSV strategy development, EUDAMED readiness, regulatory intelligence monitoring, and incident reporting support aligned with evolving European Commission expectations.

What Is the EU MIR Form?

The Manufacturer Incident Report (MIR) form is the official EU reporting document used for:

• Serious incident reporting 
• Field Safety Corrective Actions (FSCAs) 
• Vigilance communication with Competent Authorities 
• MDR post-market surveillance activities 
• EUDAMED vigilance data submission 

The MIR form plays a central role in ensuring manufacturers fulfill their obligations under EU MDR Articles 87–92 concerning vigilance and post-market monitoring.

Why MIR Version 7.3.1 Was Introduced

The existing MIR Version 7.2.1 has been used since 2020. However, multiple regulatory and technical developments created the need for a revised reporting framework.

1. EUDAMED Integration Requirements

The transition toward electronic vigilance reporting requires:

• Structured XML reporting 
• Standardized digital data fields 
• Harmonized submission formats 
• Automated vigilance workflows 
• Improved interoperability between authorities 

MIR Version 7.3.1 was designed to support future EUDAMED vigilance module integration.

2. Post-Brexit Regulatory Changes

Following the United Kingdom’s exit from the European Union, older MIR versions required updates to remove or revise:

• Legacy EU conformity references 
• U.K.-specific pathways 
• Historical market access references 

These changes became necessary for regulatory consistency across EU MDR systems.

3. EU–Switzerland MRA Expiration

The expiration of the Mutual Recognition Agreement (MRA) between the EU and Switzerland created additional reporting complexities involving:

• Swiss Authorized Representatives 
• Importer identification fields 
• Market access documentation 
• Regulatory representation structures 

MIR 7.3.1 aimed to modernize these reporting requirements.

Technical Challenges with MIR Version 7.3.1

Despite its intended improvements, manufacturers and Authorized Representatives reported widespread functionality issues with MIR Version 7.3.1, including the SB 10573 revision.

1. Data Retention Failures

Several users reported that Section 2.5a failed to properly save distribution data entries, even when using Adobe Acrobat Pro.

Industry Impact

• Repeated manual data entry 
• Lost reporting information 
• Submission delays 
• Increased administrative burden 
• Higher risk of reporting inaccuracies 

2. Annex A Selection Errors

In Section 4.3.1a, users experienced difficulties selecting only Annex A when documenting similar serious incidents.

Compliance Concerns

This created complications for:

• Devices with limited incident histories 
• Narrow vigilance scenarios 
• Targeted risk evaluations 
• Specialized device categories 

3. Validation and Workflow Failures

Even organizations using the required Adobe Acrobat Pro software encountered major usability problems such as:

• Locked data fields 
• From crashes 
• Auto-population errors 
• Failed validation checks 
• Inconsistent data formatting 
• Submission interruptions 

These issues significantly reduced operational efficiency for vigilance teams.

4. AR and Manufacturer Coordination Problems

Cross-functional review workflows became increasingly difficult due to inconsistent form behavior.

Common Issues Included

• Validation mismatches 
• Data synchronization failures 
• Internal review disruptions 
• Submission inconsistencies 
• Delayed incident reporting timelines 

These challenges highlighted that MIR Version 7.3.1 was not fully ready for large-scale implementation.

Lack Of Official Regulatory Communication

One of the most difficult aspects for industry stakeholders has been the absence of formal communication from European authorities.

Currently, no official public announcement fully clarifies:

• Known MIR 7.3.1 defects 
• Corrective action timelines 
• Final implementation schedules 
• Updated guidance documentation 
• Interim compliance expectations 
• Transition requirements for manufacturers 

Although the MDCG PMSV Working Group is reportedly evaluating the situation, the lack of formal clarification has created substantial uncertainty across the medical device industry.

Expected Timeline for MIR 7.3.1 Implementation

Based on current industry observations and European Commission webpage updates, manufacturers should expect the following timeline.

This indicates that MIR Version 7.2.1 will likely remain the primary operational reporting format throughout most of 2025.

Why This Delay Matters for MDR Compliance

The MIR form directly impacts several critical areas of MDR post-market surveillance and vigilance compliance.

1. EUDAMED Vigilance Readiness

Organizations preparing XML-based reporting systems may need to revise implementation timelines.

Potential Impact

• Delayed software integration 
• Revised digital reporting strategies 
• Additional validation requirements 
• Updated internal data structures 

2. Authorized Representative Obligations

Authorized Representatives remain responsible for supporting vigilance compliance under MDR Article 11.

Key Challenges

• Reporting consistency 
• Accurate incident communication 
• Submission coordination 
• Documentation alignment 

3. Competent Authority Interactions

Technical reporting failures may complicate responses to Competent Authority inquiries involving:

• Serious incident investigations 
• Root cause analysis 
• FSCA reporting 
• CAPA documentation 
• Trend reporting activities 

4. Internal SOP Updates

Many organizations will need to revise vigilance procedures once the final MIR revision becomes available.

Affected Documentation

• PMS procedures 
• Vigilance SOPs 
• Incident escalation workflows 
• Reporting templates 
• Regulatory communication processes 

Recommended Actions for Manufacturers (2025–2026)

Manufacturers should take a proactive and flexible approach while awaiting the finalized MIR update.

1. Continue Using MIR Version 7.2.1

At present, MIR 7.2.1 remains the most stable and operationally reliable option.

2. Monitor EC and MDCG Publications Closely

Weekly regulatory intelligence monitoring is strongly recommended.

Focus Areas

• EC PMSV webpage updates 
• MDCG guidance publications 
• EUDAMED announcements 
• Vigilance transition notices 
• Competent Authority Communications 

3. Build Flexibility into Vigilance SOPs

Organizations should prepare procedures that allow rapid adaptation once the new form is released.

4. Validate Adobe Software Configurations

Ensuring compatibility across all quality and regulatory teams may reduce future reporting disruptions.

5. Prepare EUDAMED-Compatible Data Structures

The future MIR framework will likely require structured electronic vigilance reporting.

Preparation Areas

• XML readiness 
• Data mapping 
• Structured reporting systems 
• Digital workflow integration 
• Automated submission capability 

6. Strengthen Manufacturer–AR Collaboration

Early coordination can reduce reporting inconsistencies and submission delays during the transition period.

Impact On Global Medical Device Manufacturers

Manufacturers marketing devices across multiple EU jurisdictions may experience expanded compliance obligations.

Organizations with strong PMSV infrastructure will be better positioned to adapt efficiently.

Future Trends in EU Vigilance Reporting

The MIR 7.3.1 transition reflects broader modernization efforts across European medical device regulation.

• Increased digital vigilance reporting 
• Expanded EUDAMED integration 
• Structured XML submissions 
• Greater automation of PMS workflows 
• Enhanced Competent Authority Oversight 
• More harmonized EU reporting systems 
• Stronger lifecycle vigilance monitoring 

The future EU vigilance landscape will likely become increasingly data-driven and technology-enabled.

Quick Facts

• MIR Version 7.3.1 implementation is likely delayed until 2026 
• MIR Version 7.2.1 remains the recommended reporting format 
• EUDAMED integration is a major driver behind the update 
• Multiple technical and validation issues affected Version 7.3.1  
• MDR vigilance obligations remain fully active despite the delay  
• Manufacturers should maintain flexible PMSV procedures 
• Regulatory intelligence monitoring is essential during the transition 

Why This Matters

The MIR form remains one of the most critical components of EU MDR vigilance compliance.

Organizations that fail to adapt effectively may face:

• Reporting delays 
• Increased Competent Authority scrutiny 
• Nonconformities during audits 
• Vigilance submission errors 
• Regulatory enforcement risks 
• Disruptions to EU market access 

Proactive planning and continuous monitoring will be essential for maintaining uninterrupted MDR compliance during the MIR transition period.

How Maven Regulatory Solutions Supports MDR Vigilance Compliance

Our Services

• EU MDR vigilance reporting support 
• MIR form completion and review 
• EUDAMED readiness consulting 
• PMSV SOP development 
• Serious incident investigation support 
• FSCA regulatory strategy guidance 
• Authorized Representative coordination 
• MDR regulatory intelligence monitoring 
• Vigilance workflow optimization 
• Compliance gap assessments 

Why Choose Maven

• Deep expertise in EU MDR vigilance requirements 
• Strong regulatory affairs and PMSV capabilities 
• Up-to-date regulatory intelligence tracking 
• End-to-end compliance support 
• Practical guidance for global manufacturers 
• Experience supporting multinational MDR strategies 

Learn more at Maven Regulatory Solutions.

Need Support with EU MDR Vigilance Compliance?

Maven Regulatory Solutions helps medical device manufacturers navigate evolving EU MDR vigilance requirements with confidence.

We Help You With

• MIR reporting compliance 
• EUDAMED vigilance readiness 
• PMSV workflow optimization 
• Incident investigation documentation 
• MDR SOP development 
• Authorized Representative coordination 
• Regulatory intelligence monitoring 

Partner With Maven Regulatory Solutions To:

• Strengthening MDR vigilance compliance
• Reduce reporting risks
• Improve audit readiness
• Streamline PMSV processes
• Prepare for future MIR transitions
• Maintain uninterrupted EU market access

Contact Maven Regulatory Solutions today to strengthen your EU MDR vigilance strategy.

Conclusion

The expected delay of MIR Version 7.3.1 implementation into 2026 highlights the complexity of modernizing EU MDR vigilance systems.

While the revised form aims to support EUDAMED integration and improved reporting harmonization, current technical limitations indicate that additional refinement is necessary before mandatory adoption.

Manufacturers should continue using MIR Version 7.2.1 while proactively preparing for future transition requirements through:

• Strong vigilance procedures 
• Flexible SOP frameworks 
• EUDAMED readiness planning 
• Continuous regulatory intelligence monitoring 
• Enhanced manufacturer–AR coordination 

Organizations that act early and maintain adaptable compliance systems will be best positioned to navigate the evolving MDR vigilance landscape successfully.

FAQs

1. What is the EU MIR form?

The Manufacturer Incident Report (MIR) form is the official EU MDR vigilance reporting form used for serious incidents and FSCAs.

2. Why is MIR Version 7.3.1 delayed?

Technical functionality issues, validation failures, and usability problems have delayed implementation.

3. When will MIR 7.3.1 likely become mandatory?

Current industry expectations suggest implementation may begin around March 2026.

4. Which MIR version should manufacturers currently use?

MIR Version 7.2.1 remains the most stable and recommended version for ongoing reporting.

5. How does this affect EUDAMED readiness?

Manufacturers may need to revise timelines for XML-based vigilance reporting integration.

6. What are the biggest challenges with MIR 7.3.1?

Common issues include data retention failures, form crashes, validation errors, and workflow inconsistencies.

7. How can Maven help with MDR vigilance compliance?

Maven supports MIR reporting, EUDAMED readiness, vigilance SOP development, PMSV strategy, and ongoing MDR regulatory intelligence.